ClinicalTrials.Veeva
Menu

Find clinical trials for Asthma in Warszawa, Mazowieckie

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pulmonary Eosinophilia
Chronic Obstructive Pulmonary Disease
Obstructive Lung Diseases
Allergic Rhinitis
Nasal Polyps
Rhinitis
Lung Diseases

Asthma trials near Warszawa, Mazowieckie, POL:

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. (EXHALE-2)

This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma...

Enrolling
Asthma
Asthma; Eosinophilic
Drug: Placebo
Drug: Dexpramipexole Dihydrochloride

Phase 3

Areteia Therapeutics

Piaseczno, Poland and 125 other locations

The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma...

Enrolling
Asthma Attack
Asthma; Eosinophilic
Drug: Placebo
Drug: Dexpramipexole Dihydrochloride

Phase 3

Areteia Therapeutics

Piaseczno, Poland and 117 other locations

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function

Enrolling
Moderate to Severe Asthma
Drug: ICS-LABA
Other: placebo

Phase 2

Incyte
Incyte

Warszawa, Poland and 96 other locations

and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma...

Enrolling
Asthma
Drug: Atuliflapon
Drug: Placebo

Phase 2

AstraZeneca
AstraZeneca

Warszawa, Poland and 369 other locations

variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma...

Enrolling
Asthma
Drug: BFF pMDI 320/9 μg
Drug: BFF MDI 320/9.6 μg

Phase 3

AstraZeneca
AstraZeneca

Piaseczno, Poland and 478 other locations

compared to omalizumab* To evaluate the effect of dupilumab on asthma control at Week 24 compared to omalizumab* To evaluate the safety of ...

Active, not recruiting
Asthma
Chronic Rhinosinusitis With Nasal Polyps
Drug: Omalizumab
Drug: Placebo

Phase 4

Sanofi
Sanofi

Warszawa, Mazowieckie, Poland and 94 other locations

Locations recently updated

birch pollen-induced allergic rhinoconjunctivitis, with or without asthma, when treated before and during the pollen season.Approximately 69...

Active, not recruiting
Birch Pollen Allergy
Allergic Rhinoconjunctivitis
Drug: STALORAL® Birch 300 IR

Phase 3

Stallergenes Greer
Stallergenes Greer

Warsaw, Poland and 61 other locations

This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with CRSwNP.

Active, not recruiting
Nasal Polyps
Drug: Placebo
Biological: Depemokimab (GSK3511294)

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Nadarzyn, Poland and 84 other locations

This is a randomized, double-blind, placebo-controlled, parallel-group, international, multicenter, Phase 3 study to evaluate the efficacy and safety...

Active, not recruiting
Nasal Polyposis
Biological: Benralizumab 30 mg
Biological: Matched placebo

Phase 3

AstraZeneca
AstraZeneca

Nadarzyn, Poland and 115 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems